The estimated Net Worth of Plc Gsk is at least $1.5 Miliard dollars as of 7 December 2023. Plc Gsk owns over 3,300,000 units of Pandion Therapeutics stock worth over $839,724,848 and over the last 20 years Plc sold PAND stock worth over $656,033,715.
Sign up
Plc Gsk PAND stock SEC Form 4 insiders trading
Plc has made over 31 trades of the Pandion Therapeutics stock since 2012, according to the Form 4 filled with the SEC. Most recently Plc bought 3,300,000 units of PAND stock worth $16,500,000 on 7 December 2023.
The largest trade Plc's ever made was selling 32,005,260 units of Pandion Therapeutics stock on 20 May 2021 worth over $392,064,435. On average, Plc trades about 1,475,496 units every 85 days since 2004. As of 7 December 2023 Plc still owns at least 13,983,761 units of Pandion Therapeutics stock.
You can see the complete history of Plc Gsk stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Plc Gsk's mailing address?
Plc's mailing address filed with the SEC is 980 GREAT WEST ROAD, , BRENTFORD MIDDLESEX, X0, TW8 9GS.
Insiders trading at Pandion Therapeutics
Over the last 4 years, insiders at Pandion Therapeutics have traded over $0 worth of Pandion Therapeutics stock and bought 1,743,632 units worth $30,815,954 . The most active insiders traders include Plc Gsk, Capital Management, L.P.Kol... oraz Daniel J. Becker. On average, Pandion Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $9,518,646. The most recent stock trade was executed by Daniel J. Becker on 19 November 2020, trading 197,716 units of PAND stock currently worth $2,989,466.
What does Pandion Therapeutics's logo look like?
Complete history of Plc Gsk stock trades at Amicus Therapeutics Inc, Applied Genetic Technologies Corp, ChemoCentryx Inc, Concert Pharmaceuticals Inc, CRISPR Therapeutics AG, Genocea Biosciences Inc, HTG Molecular Diagnostics Inc, Innoviva Inc, Theravance Biopharma Inc, Wave Life Sciences, Quest Diagnostics, Spero Therapeutics Inc, Telesis Bio Inc, Liquidia Corp, Turning Point Therapeutics Inc, Morphic Inc, Fulcrum Therapeutics Inc, Progyny Inc, Bicycle Therapeutics plc, Principia Biopharma, Nkarta oraz Pandion Therapeutics
Pandion Therapeutics executives and stock owners
Pandion Therapeutics executives and other stock owners filed with the SEC include:
-
Capital Management, L.P.Kol...,
-
Nancy Stagliano,
Director -
Vikas Goyal,
See Remarks -
Joanne L. Viney,
See Remarks -
Partners Gp Viii, L.L.C.Pol...,
-
Rizzuto Carlo,
Director -
Jill Carroll,
Director -
Katina Dorton,
Director -
Donald Frail,
Director -
Christopher Fuglesang,
Director -
Gregg Beloff,
See Remarks -
Alan L Crane,
Director -
Mitchell Mutz,
Director -
Eric D Larson,
Vice President, Finance -
Daniel J. Becker,
Director -
Rahul Kakkar,
Chief Executive Officer -
Plc Gsk,
Director -
John Sundy,
Chief Medical Officer -
Edward D. Freedman,
Chief Operating Officer